Company Analysis
Sign in

Humacyte, Inc. (HUMA)

Nasdaq: HUMA · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.9
◀ Past 4.2● Present 3.2▶ Future 4.3
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$2.0M
Net income-$40.8M+72.5%
Earnings per share$-0.26+79.4%
Operating cash flow-$105M-7.1%
Cash$50.9M-46.6%
Debt$35.4M
Shareholders’ equity$3.1M+105.9%
Shares, diluted158.2M+33.5%
Return on equity-1313.4%
The recordfrom its filings
Filings in 202655
Newest filingNov 10 · 10-Q
Annual reportMar 27, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$100,000
Insider buys, 12 months$100,000
Patents granted14
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $2.4MNet income -$94.8MCash from operations -$88.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 28, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton HUMA · research, not advice